VEGFA and Stroke: Compared with nonuse, intravitreal anti‐VEGF agent use was associated with an increased risk of stroke within 90 days of anti‐VEGF treatment in 2.9% of the nAMD‐patients [Risk Ratio (RR) 1.27, 95% confidence interval (CI) 1.22; 1.33] compared to non‐users.